Marker receives approval from the USAN council, INN committee for neldaleucel

Marker Therapeutics announced today that the United States Adopted Names, USAN, Council, and the World Health Organization, WHO, International Nonproprietary Names, INN, expert committee has approved “neldaleucel” as the nonproprietary name for MT-601, a multi-tumor associated antigen-specific T cell product candidate for the treatment of patients with lymphoma. “The assignment of the nonproprietary name to MT-601 represents a significant milestone as we advance this potential treatment for patients with lymphoma,” said Juan Vera, M.D., President and CEO of Marker Therapeutics. “The INN and USAN naming process meticulously evaluates proposed drug names for adherence to nomenclature guidelines and potential conflicts, followed by expert consensus and public review. The USAN and WHO INN approval of neldaleucel allows us to establish a universally recognized and conflict-free nonproprietary drug name for MT-601 and represents an important step in our path to ultimately market the drug.”